Valuation: Applied Therapeutics, Inc.

Market Cap 15.25M 13.55M 12.64M 11.52M 21.73M 1.47B 21.94M 153M 59.29M 749M 57.24M 56M 2.4B P/E 2023
-2.36x
P/E 2024 -1.13x
Enterprise Value -61.36M -54.52M -50.88M -46.38M -87.47M -5.9B -88.28M -616M -239M -3.02B -230M -225M -9.68B EV / Sales 2023
20,974,366x
EV / Sales 2024 50,596,512x
Free-Float
95.24%
Yield 2023 *
-
Yield 2024 -
1 day+0.19%
Current year+3.00%
Current year 0.09
Extreme 0.09
0.11
1 year 0.09
Extreme 0.09
1.5
3 years 0.09
Extreme 0.09
10.62
5 years 0.09
Extreme 0.09
19.14
10 years 0.09
Extreme 0.09
57.39
Manager TitleAgeSince
President - 02/02/2026
Corporate Secretary - 02/02/2026
Corporate Officer/Principal - 20/01/2025
Director TitleAgeSince
Director/Board Member - 02/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
03/02/26 Issuer sale

Director

328,690 0.2278%
03/02/26 Issuer sale

Director

393,053 0.2724%
03/02/26 Issuer sale

Director

328,690 0.2278%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-.--%-85.29%-95.86% 15.7M
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
-0.82%-4.50%+26.35%+33.17% 42.91B
-0.07%+0.86%+352.39%+689.99% 44.13B
-1.64%-2.13%+2.32%+97.86% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+0.82%-7.26%-28.48%+330.73% 23.71B
Average -0.31%-0.58%+38.55%+132.91% 39.25B
Weighted average by Cap. -0.06%-0.40%+57.42%+150.04%

Financials

2023 2024
Net sales 9.99 8.88 8.29 7.55 14.25 960.66 14.38 100.29 38.86 491.1 37.52 36.7 1.58K 0.46 0.4 0.38 0.34 0.65 43.74 0.65 4.57 1.77 22.36 1.71 1.67 71.76
Net income -120M -106M -99.32M -90.52M -171M -11.51B -172M -1.2B -466M -5.89B -450M -440M -18.89B -106M -93.85M -87.59M -79.84M -151M -10.15B -152M -1.06B -411M -5.19B -397M -388M -16.66B
Net Debt -49.12M -43.64M -40.73M -37.13M -70.02M -4.72B -70.68M -493M -191M -2.41B -184M -180M -7.75B -76.6M -68.06M -63.52M -57.9M -109M -7.36B -110M -769M -298M -3.76B -288M -281M -12.08B
Logo Applied Therapeutics, Inc.
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Employees
28
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. APLT Stock